Small Cell Lung Cancer
Clinical research in limited-stage small cell lung cancer focuses on patients without disease progression after chemoradiotherapy, with interest in consolidation therapy and survival outcomes such as overall survival and progression-free survival.
- Limited-stage small cell lung cancer
- Consolidation therapy
- Overall survival
- Progression-free survival
Research activities in this area include immunotherapy-based combinations for post-chemoradiotherapy disease control.
Hepatocellular Carcinoma
Studies in advanced hepatocellular carcinoma examine first-line treatment strategies, with attention to immunotherapy and anti-angiogenic therapy combinations and their impact on overall survival.
- Advanced hepatocellular carcinoma
- First-line therapy
- Immunotherapy
- Anti-angiogenic therapy
The therapeutic focus includes treatment approaches for unresectable liver cancer in the advanced disease setting.
Immune Checkpoint Modulation
The sponsor’s portfolio includes immune checkpoint inhibitor research centered on toripalimab and tifcemalimab, reflecting interest in tumour immunology and combination regimens across solid tumours.
- Toripalimab
- Tifcemalimab
- Immune checkpoint inhibitor
- Tumour immunology
These studies explore how immunotherapy can be integrated with other cancer treatments in difficult-to-treat malignancies.
Combination Oncology Therapy
Clinical interest extends to combination oncology therapy, including pairing PD-1 blockade with multikinase inhibition and other treatment backbones in solid tumours.
- PD-1 blockade
- Multikinase inhibition
- Solid tumours
- Combination oncology therapy
Trial activity is concentrated in oncology settings where combined systemic approaches are used to address advanced cancer.
